BioInteractions first with body-friendly surface:
This article was originally published in Clinica
Executive Summary
BioInteractions has become the first UK company to receive US FDA clearance to market a biocompatible surface for oxygenators. The company developed the Trillium surface with US firm Avecor for its Affinity oxygenator. BioInteractions is collaborating in a number of programmes with major manufacturers to surface treat medical devices. These products should reach the market within the next three years, the company said.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.